182 related articles for article (PubMed ID: 34553039)
1. Systemic delivery of TNF-armed myxoma virus plus immune checkpoint inhibitor eliminates lung metastatic mouse osteosarcoma.
Christie JD; Appel N; Canter H; Achi JG; Elliott NM; de Matos AL; Franco L; Kilbourne J; Lowe K; Rahman MM; Villa NY; Carmen J; Luna E; Blattman J; McFadden G
Mol Ther Oncolytics; 2021 Sep; 22():539-554. PubMed ID: 34553039
[TBL] [Abstract][Full Text] [Related]
2. Systemic Delivery of mLIGHT-Armed Myxoma Virus Is Therapeutic for Later-Stage Syngeneic Murine Lung Metastatic Osteosarcoma.
Christie JD; Appel N; Zhang L; Lowe K; Kilbourne J; Daggett-Vondras J; Elliott N; Lucas AR; Blattman JN; Rahman MM; McFadden G
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053501
[TBL] [Abstract][Full Text] [Related]
3. Transplantation of autologous bone marrow pre-loaded
Villa NY; Rahman MM; Mamola J; Sharik ME; de Matos AL; Kilbourne J; Lowe K; Daggett-Vondras J; D'Isabella J; Goras E; Chesi M; Bergsagel PL; McFadden G
Oncotarget; 2022; 13():490-504. PubMed ID: 35251496
[TBL] [Abstract][Full Text] [Related]
4. Autologous Transplantation Using Donor Leukocytes Loaded
Villa NY; Rahman MM; Mamola J; D'Isabella J; Goras E; Kilbourne J; Lowe K; Daggett-Vondras J; Torres L; Christie J; Appel N; Cox AL; Kim JB; McFadden G
Mol Ther Oncolytics; 2020 Sep; 18():171-188. PubMed ID: 32695875
[TBL] [Abstract][Full Text] [Related]
5. Ex Vivo Oncolytic Virotherapy with Myxoma Virus Arms Multiple Allogeneic Bone Marrow Transplant Leukocytes to Enhance Graft versus Tumor.
Lilly CL; Villa NY; Lemos de Matos A; Ali HM; Dhillon JS; Hofland T; Rahman MM; Chan W; Bogen B; Cogle C; McFadden G
Mol Ther Oncolytics; 2017 Mar; 4():31-40. PubMed ID: 28345022
[TBL] [Abstract][Full Text] [Related]
6. Combination of LIGHT (TNFSF14)-Armed Myxoma Virus Pre-Loaded into ADSCs and Gemcitabine in the Treatment of Experimental Orthotopic Murine Pancreatic Adenocarcinoma.
Jazowiecka-Rakus J; Sochanik A; Hadryś A; Fidyk W; Chmielik E; Rahman MM; McFadden G
Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454928
[TBL] [Abstract][Full Text] [Related]
7. Ex Vivo Virotherapy with Myxoma Virus to Treat Cancer.
Villa NY; Franco LS; McFadden G
Methods Mol Biol; 2020; 2058():95-110. PubMed ID: 31486033
[TBL] [Abstract][Full Text] [Related]
8. Dual-Armed Oncolytic Myxoma Virus Encoding IFN-γ and CD47 Promotes Lymphocyte Infiltration and Tumor Suppression of Syngeneic Murine Melanoma.
Woo JK; Kim TG; Im NY; Son KY; Cho M; Jeong YJ; Hong JI; Kang B; Enkhtaivan G; Cho NH; Alain T; Park DG; Lee YS
Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835397
[TBL] [Abstract][Full Text] [Related]
9. M011L-deficient oncolytic myxoma virus induces apoptosis in brain tumor-initiating cells and enhances survival in a novel immunocompetent mouse model of glioblastoma.
Pisklakova A; McKenzie B; Zemp F; Lun X; Kenchappa RS; Etame AB; Rahman MM; Reilly K; Pilon-Thomas S; McFadden G; Kurz E; Forsyth PA
Neuro Oncol; 2016 Aug; 18(8):1088-1098. PubMed ID: 26962017
[TBL] [Abstract][Full Text] [Related]
10. Myxoma Virus Expressing LIGHT (TNFSF14) Pre-Loaded into Adipose-Derived Mesenchymal Stem Cells Is Effective Treatment for Murine Pancreatic Adenocarcinoma.
Jazowiecka-Rakus J; Hadrys A; Rahman MM; McFadden G; Fidyk W; Chmielik E; Pazdzior M; Grajek M; Kozik V; Sochanik A
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33808692
[TBL] [Abstract][Full Text] [Related]
11. Myxoma Virus-Loaded Mesenchymal Stem Cells in Experimental Oncolytic Therapy of Murine Pulmonary Melanoma.
Jazowiecka-Rakus J; Sochanik A; Rusin A; Hadryś A; Fidyk W; Villa N; Rahman MM; Chmielik E; Franco LS; McFadden G
Mol Ther Oncolytics; 2020 Sep; 18():335-350. PubMed ID: 32775618
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic virotherapy for small-cell lung cancer induces immune infiltration and prolongs survival.
Kellish P; Shabashvili D; Rahman MM; Nawab A; Guijarro MV; Zhang M; Cao C; Moussatche N; Boyle T; Antonia S; Reinhard M; Hartzell C; Jantz M; Mehta HJ; McFadden G; Kaye FJ; Zajac-Kaye M
J Clin Invest; 2019 Apr; 129(6):2279-2292. PubMed ID: 31033480
[TBL] [Abstract][Full Text] [Related]
13. Myxoma virus expressing a fusion protein of interleukin-15 (IL15) and IL15 receptor alpha has enhanced antitumor activity.
Tosic V; Thomas DL; Kranz DM; Liu J; McFadden G; Shisler JL; MacNeill AL; Roy EJ
PLoS One; 2014; 9(10):e109801. PubMed ID: 25329832
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma.
Vijayakumar G; Palese P; Goff PH
EBioMedicine; 2019 Nov; 49():96-105. PubMed ID: 31676387
[TBL] [Abstract][Full Text] [Related]
15. Metastatic tumor cells detection and anti-metastatic potential with vesicular stomatitis virus in immunocompetent murine model of osteosarcoma.
Johan MP; Kubo T; Furuta T; Sakuda T; Sakaguchi T; Nakanishi M; Ochi M; Adachi N
J Orthop Res; 2018 Sep; 36(9):2562-2569. PubMed ID: 29637599
[TBL] [Abstract][Full Text] [Related]
16. Synergistic anti-tumor efficacy of oncolytic influenza viruses and B7-H3 immune- checkpoint inhibitors against IC-resistant lung cancers.
Masemann D; Meissner R; Schied T; Lichty BD; Rapp UR; Wixler V; Ludwig S
Oncoimmunology; 2021 Feb; 10(1):1885778. PubMed ID: 33643696
[TBL] [Abstract][Full Text] [Related]
17. Myxoma virus infection promotes NK lysis of malignant gliomas in vitro and in vivo.
Ogbomo H; Zemp FJ; Lun X; Zhang J; Stack D; Rahman MM; McFadden G; Mody CH; Forsyth PA
PLoS One; 2013; 8(6):e66825. PubMed ID: 23762498
[TBL] [Abstract][Full Text] [Related]
18. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
Vijayakumar G; McCroskery S; Palese P
J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
[TBL] [Abstract][Full Text] [Related]
19. Synergistic Combination of Oncolytic Virotherapy and Immunotherapy for Glioma.
Tang B; Guo ZS; Bartlett DL; Yan DZ; Schane CP; Thomas DL; Liu J; McFadden G; Shisler JL; Roy EJ
Clin Cancer Res; 2020 May; 26(9):2216-2230. PubMed ID: 32019860
[TBL] [Abstract][Full Text] [Related]
20. Ex vivo virotherapy with myxoma virus does not impair hematopoietic stem and progenitor cells.
Villa NY; Bais S; Chan WM; Meacham AM; Wise E; Rahman MM; Moreb JS; Rosenau EH; Wingard JR; McFadden G; Cogle CR
Cytotherapy; 2016 Mar; 18(3):465-80. PubMed ID: 26857235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
